Secondary Hypogonadism Relapse Prevention Strategies: A Clinical Guide

What "relapse" means in secondary hypogonadism

Secondary hypogonadism is diagnosed when a man has repeatedly low morning total testosterone alongside LH and FSH that are low or fail to rise appropriately, indicating the testes could respond to signal but are not receiving one. Relapse describes the return of biochemical and symptomatic hypogonadism after a period of normalization, whether that normalization came from treating an underlying cause, from a course of enclomiphene or hCG, or from a trial off testosterone therapy.

Relapse is common in this condition because the underlying disruption to GnRH pulsatility is rarely fixed once and for all. The HPG axis depends on GnRH release roughly every one to two hours; conditions that blunt this pulse pattern, including chronic energy excess, opioid exposure, hyperprolactinemia, iron overload, and prior exogenous androgen use, tend to recur or persist unless actively managed. When the driver returns or was never resolved, testosterone falls again regardless of how effective the initial treatment was.

A 2015 review of protocols used to manage androgen-induced secondary hypogonadism (hypogonadism following exogenous testosterone or anabolic-androgenic steroid use) catalogued the hCG- and SERM-based approaches used clinically and informally to restart endogenous testosterone production after axis suppression, and noted that recovery time and completeness vary considerably between individuals (Rahnema et al. 2015). This is one of the few papers that directly addresses relapse-style axis recovery rather than de novo hypogonadism, and it is the anchor for several of the treatment-selection points below; readers and clinicians should review it directly before applying specific protocol details, since dosing conventions have evolved since 2015.

Which cause are you dealing with, and can it be reversed?

Relapse prevention starts with sorting the underlying driver into reversible versus structural, because that distinction determines whether the long-term goal is axis restoration or lifelong replacement.

Commonly reversible or modifiable drivers:

• Obesity. Adipose tissue aromatizes testosterone to estradiol, and elevated estradiol suppresses GnRH release. Weight loss in obese men with functional hypogonadism has been associated with increases in testosterone in observational and interventional studies, though the exact magnitude varies by cohort and should not be quoted as a fixed number for an individual patient.
• Opioid-induced androgen deficiency. Long-term opioid therapy suppresses the HPG axis in a substantial proportion of chronic users. If opioids cannot be tapered, testosterone-preserving management becomes an ongoing commitment rather than a short course.
• Hyperprolactinemia. Elevated prolactin directly suppresses GnRH pulsatility. Markedly elevated prolactin usually points to a prolactinoma and warrants dopamine agonist therapy and pituitary imaging; normalizing prolactin often restores spontaneous testosterone production.
• Obstructive sleep apnea. OSA is associated with reduced nocturnal testosterone pulses, and treating OSA has been reported to raise morning testosterone in some studies, though effect sizes differ across the literature and CPAP alone does not reliably normalize testosterone in every patient.
• Prior exogenous androgen or anabolic steroid use. This suppresses the axis by the same feedback mechanism as illness-related excess estrogen or testosterone, and recovery protocols (hCG, SERMs) are specifically discussed in the androgen-induced hypogonadism literature referenced above.

Less common but treatable causes include hereditary hemochromatosis (iron deposition in the pituitary) and hypothyroidism, which can alter testosterone-binding proteins and complicate interpretation of total testosterone. A baseline ferritin and TSH are reasonable in a man with secondary hypogonadism of unclear cause.

Structural or fixed causes, such as congenital hypogonadotropic hypogonadism (including Kallmann syndrome), pituitary tumors after surgery or radiation, and traumatic brain injury with hypothalamic damage, are not expected to resolve with lifestyle change. In these cases, relapse prevention is really about choosing the right long-term maintenance strategy rather than aiming for a drug-free axis.

Should you use enclomiphene or hCG instead of testosterone?

This is the central relapse-prevention decision for men who have not completed their families or who want to preserve the option of stopping therapy later.

Exogenous testosterone (TRT) replaces the hormone directly but further suppresses LH and FSH, because the pituitary senses adequate androgen and stops signaling the testes. This is why testosterone therapy reliably relapses back to hypogonadal levels if it is stopped abruptly: the axis has not been asked to function on its own during treatment. TRT also suppresses spermatogenesis in most men within months of starting, an effect that is not always fully reversible and can take many months to resolve after stopping.

Enclomiphene citrate is a selective estrogen receptor modulator that blocks estrogen receptors in the hypothalamus, which increases GnRH, LH, FSH, and downstream testosterone while keeping the axis active rather than replacing its output. Because it works upstream, it does not suppress spermatogenesis the way testosterone does. As of mid-2025, enclomiphene is not FDA-approved for male hypogonadism; it has previously been the subject of complete response letters from the FDA when submitted for approval, and its clinical use for this indication remains off-label. Clinicians should document informed consent accordingly and verify current regulatory status before prescribing, since approval status can change.

hCG (human chorionic gonadotropin) mimics LH and stimulates Leydig cell testosterone production directly, without acting on FSH. It has long clinical experience in hypogonadotropic hypogonadism, including in men who have previously used exogenous androgens, and can preserve or restart spermatogenesis, particularly when FSH function is intact. For men with combined LH and FSH deficiency and impaired sperm production, adding recombinant FSH to hCG is a recognized approach for inducing spermatogenesis, though it adds cost and injection burden.

When TRT is the appropriate choice. Some men cannot tolerate or access enclomiphene or hCG, have completed childbearing, or have a structural cause unlikely to respond to axis stimulation. In these cases, standard testosterone formulations (intramuscular, subcutaneous, or transdermal) are appropriate, and relapse prevention shifts from axis preservation to consistent dosing, monitoring for over-replacement (elevated hematocrit, suppressed HDL), and lifestyle management of comorbid conditions.

Which lifestyle changes actually move the needle?

Medication without addressing modifiable drivers rarely produces durable remission. The table below is a practical decision framework for matching a reader's situation to the evidence-supported next step, rather than a generic checklist.

Beyond weight and the specific drivers above, sleep duration, resistance exercise, alcohol intake, and heavy cannabis use all have plausible mechanistic links to HPG axis suppression based on smaller studies, but the size of their individual effect on testosterone in a given patient is not reliably predictable from the literature and should not be quoted as a guaranteed number. These factors are worth addressing as part of general health, but a reader should not expect lifestyle change alone to substitute for medical evaluation if testosterone remains low after a genuine attempt at correction.

How often should testosterone be rechecked to catch a relapse early?

Consensus guidance from the Endocrine Society recommends confirming low testosterone with at least two separate morning measurements before diagnosis, because testosterone has meaningful day-to-day and diurnal variation; morning blood draws (roughly 7 to 10 a.m.) are recommended for this reason. During stable maintenance therapy, testosterone is typically rechecked a few months after starting or adjusting treatment, then at longer intervals once stable, per standard guideline-based follow-up.

For men attempting to reduce or stop treatment, a tighter schedule is reasonable given the relapse risk:

• First few months after a dose change: testosterone and LH checked roughly monthly
• Through the first year: testosterone and LH every few months
• Beyond a year, if stable: every six months to a year

Exact intervals should be set with the treating clinician based on the cause, the agent used, and how the patient tolerated prior changes; the schedule above is a reasonable starting framework, not a fixed protocol validated in a dedicated trial.

At each visit, prolactin, estradiol, a complete blood count (to catch over-replacement on TRT), and periodic bone density assessment for men with a year or more of untreated hypogonadism are reasonable additions, consistent with general Endocrine Society guidance on hypogonadism and bone health. A TSH is worth checking periodically because hypothyroidism can alter testosterone-binding globulin and confound interpretation.

Symptom tracking with a validated instrument (such as the Aging Males' Symptoms scale) alongside labs is useful because symptoms and biochemistry do not always move together; a symptomatic man with stable testosterone may have a non-hormonal contributor such as depression, while a man whose symptoms are unchanged but whose testosterone has fallen has a biochemical relapse that needs its own management.

What should happen when levels fall again?

Relapse is a predictable, manageable event, not evidence that treatment failed. A reasonable approach when a previously stable patient develops two consecutive low morning testosterone values with symptoms is:

1. Re-check for a new or worsening reversible driver first: recent weight gain, new opioid prescription, worsening sleep apnea, elevated prolactin, or missed medication doses. This step is inexpensive and sometimes identifies an easily correctable cause.
2. If the patient is on enclomiphene or low-dose hCG, a dose increase or the addition of a second agent is a reasonable next step to discuss with the prescriber before moving to full testosterone replacement.
3. If fertility goals are complete and conservative measures have failed, transitioning to standard testosterone therapy is appropriate, with the usual monitoring for hematocrit and estradiol.

The term "functional hypogonadism," used in European Academy of Andrology and EAU statements, describes secondary hypogonadism fully explained by a reversible systemic condition such as obesity, diabetes, sleep apnea, or opioid use. In this subgroup, testosterone therapy is often framed as a bridge rather than a permanent endpoint, with a supervised trial off therapy considered after sustained correction of the underlying condition, monitored with the schedule above.

What about fertility?

Exogenous testosterone is not appropriate first-line therapy for a man who wants to father a child in the near term, because it suppresses spermatogenesis in the majority of men within a few months of starting and recovery is not universal or fast; some men remain oligospermic or azoospermic for many months to years after stopping, and a minority do not fully recover. Enclomiphene and hCG are the standard alternatives because they work upstream of the testes and are less likely to shut down sperm production, though individual response still varies.

For men who anticipate eventually needing testosterone therapy for a structural cause (for example, congenital hypogonadotropic hypogonadism), sperm cryopreservation before starting testosterone-suppressing treatment is a reasonable insurance step to discuss with a reproductive specialist, particularly if fertility is a future goal and axis recovery is uncertain.

Does behavioral support matter?

Men with secondary hypogonadism report higher rates of low mood, fatigue, and reduced motivation, and these symptoms can undermine adherence to diet, exercise, and medication schedules regardless of the biochemical picture. Addressing comorbid depression or anxiety, whether through counseling, medication, or structured support, is a reasonable part of a relapse-prevention plan because poor adherence to lifestyle change or dosing schedules is itself a relapse risk factor. Endocrine Society guidance recommends that clinicians evaluate for coexisting mood disorders as part of a complete assessment before and during testosterone therapy. Specific quantitative claims about how much behavioral support programs improve long-term testosterone maintenance were not verifiable from the source material used to build this page and have been removed rather than stated as fact; a reader interested in this question should ask their clinician about structured adherence support programs directly.

What is established, what is plausible, and what is not established

Established: Secondary hypogonadism is defined by low testosterone with low or inappropriately normal LH/FSH. Correcting a clear reversible driver (hyperprolactinemia, severe opioid dosing, uncontrolled OSA) commonly improves testosterone. Testosterone therapy suppresses the HPG axis and spermatogenesis while it is being used, and stopping it abruptly commonly leads to a return of hypogonadal levels unless the underlying driver has resolved. Morning blood draws and repeat confirmation are standard practice for diagnosis given normal variability.

Plausible but not firmly established for an individual patient: The exact size of testosterone improvement from a given amount of weight loss, CPAP therapy, or resistance exercise. Whether starting on enclomiphene or hCG instead of testosterone meaningfully lowers the rate of relapse after treatment is eventually stopped, as opposed to simply preserving fertility and axis activity during treatment.

Not established from the material reviewed for this page: Population-level relapse rates for men restarting therapy after stopping TRT, and the magnitude of benefit from structured behavioral coaching programs on long-term testosterone maintenance. Claims with specific percentages on these points should be treated as unverified until checked against a primary study, and this page does not carry a specific number that could not be traced to that source.